Clinical progress with proton pump inhibitors in acid peptic diseaseBRUNNER, Gorig.Clinical therapeutics. 1993, Vol 15, issn 0149-2918, SUPBConference Proceedings

Gastric H⁺/K⁺-ATPase inhibitorsHERLING, A. W; WEIDMANN, K.Progress in medicinal chemistry. 1994, Vol 31, pp 233-264, issn 0079-6468Article

Omeprazole before endoscopy in patients with gastrointestinal bleedingLAU, James Y; LEUNG, Wai K; NG, Enders K. W et al.The New England journal of medicine. 2007, Vol 356, Num 16, pp 1631-1640, issn 0028-4793, 10 p.Article

Phosphorylation of S⁹⁵⁵ at the protein kinase A consensus promotes maturation of the α subunit of the colonic H⁺,K⁺-ATPaseCODINA, Juan; JINGFANG LIU; BLEYER, Anthony J et al.Journal of the American Society of Nephrology. 2006, Vol 17, Num 7, pp 1833-1840, issn 1046-6673, 8 p.Article

Physical and thermal characterisation of chiral omeprazole sodium saltsMARKOVIC, Nov; AGOTONOVIC-KUSTRIN, Snezana; GLASS, Beverley et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 42, Num 1, pp 25-31, issn 0731-7085, 7 p.Conference Paper

The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glandsDUFNER, Matthias M; KIRCHHOFF, Philipp; REMY, Christine et al.American journal of physiology. Gastrointestinal and liver physiology. 2005, Vol 52, Num 6, pp G1084-G1090, issn 0193-1857Article

Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover studyKATZ, P. O; CASTELL, D. O; CHEN, Y et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 4, pp 399-406, issn 0269-2813, 8 p.Article

Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial designMADSEN, L. G; BYTZER, P.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 3, pp 365-372, issn 0269-2813, 8 p.Article

Amino acids Val¹¹⁵-Ile¹²⁶ of rat gastric H⁺-K⁺-ATPase confer high affinity for Sch-28080 to Na⁺-K⁺-ATPaseLYU, R.-M; FARLEY, R. A.American journal of physiology. Cell physiology. 1997, Vol 41, Num 5, pp C1717-C1725, issn 0363-6143Article

Stability of omeprazole in an extemporaneously prepared oral liquidQUERCIA, R. A; FAN, C; LIU, X et al.American journal of health-system pharmacy. 1997, Vol 54, Num 16, pp 1833-1836, issn 1079-2082Article

Erythema nodosum caused by omeprazoleRICCI, R. M; DEERING, K. C.Cutis (New York, NY). 1996, Vol 57, Num 6, issn 0011-4162, p. 434Article

Lack of pantoprazole drug interactions in man : an updated reviewSTEINIJANS, V. W; HUBER, R; HARTMANN, M et al.International journal of clinical pharmacology and therapeutics. 1996, Vol 34, Num 6, pp 243-262, issn 0946-1965Article

H⁺-K⁺-ATPase mediates net acid secretion in rat terminal inner medullary collecting ductWALL, S. M; TRUONG, A. V; DUBOSE, T. D et al.American journal of physiology. Renal, fluid and electrolyte physiology. 1996, Vol 40, Num 5, pp F1037-F1044, issn 0363-6127Article

Adaptation des K-ATPases rénales = Adaptation of renal K-ATPasesBuffin-Meyer, Bénédicte; Doucet, A.1996, 133 p.Thesis

Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cellsBELLI, W. A; FRYKLUND, J.Antimicrobial agents and chemotherapy. 1995, Vol 39, Num 8, pp 1717-1720, issn 0066-4804Article

Le médicament du mois: le lansoprazole (DakaR®) = Lansoprazole (DakaR®)SCHEEN, A. J.RMLG. Revue médicale de Liège. 1995, Vol 50, Num 3, pp 133-134, issn 0370-629XArticle

Dose linearity of the pharmacokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administrationBLIESATH, H; HUBER, R; HARTMANN, H et al.International journal of clinical pharmacology and therapeutics. 1994, Vol 32, Num 1, pp 44-50, issn 0946-1965Article

LansoprazoleSPENCER, C. M; FAULDS, D.Current therapeutics. 1994, Vol 35, Num 11, pp 23-26, issn 0311-905XArticle

Regulation of gastric H³-K⁺-ATPase by cAMP-dependent protein kinaseSACK, J.The Journal of surgical research. 1993, Vol 55, Num 2, pp 223-227, issn 0022-4804Article

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotypeSUGIMOTO, M; SHIRAI, N; FURUTA, T et al.Alimentary pharmacology & therapeutics. 2012, Vol 36, Num 7, pp 627-634, issn 0269-2813, 8 p.Article

The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS-A Cluster-Randomized TrialMOAYYEDI, Paul; ARMSTRONG, David; HUNT, Richard H et al.The American journal of gastroenterology. 2010, Vol 105, Num 11, pp 2341-2346, issn 0002-9270, 6 p.Article

Human lung mucous glands manifest evidence of the H⁺/K⁺-ATPase proton pumpALTMAN, Kenneth W; WALTONEN, Joshua D; TARJAN, Gabor et al.The Annals of otology, rhinology & laryngology. 2007, Vol 116, Num 3, pp 229-234, issn 0003-4894, 6 p.Article

Lack of interaction between atazanavir and lansoprazoleKOSEL, Bradley W; STOREY, Sheryl S; COLLIER, Ann C et al.AIDS (London). 2005, Vol 19, Num 6, pp 637-638, issn 0269-9370, 2 p.Article

A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringeGREMSE, D. A; DONNELLY, J. R; KUKULKA, M. J et al.Alimentary pharmacology & therapeutics. 2004, Vol 19, Num 11, pp 1211-1215, issn 0269-2813, 5 p.Article

Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazoleFRESTON, J. W; PILMER, B. L; CHIU, Y.-L et al.Alimentary pharmacology & therapeutics. 2004, Vol 19, Num 10, pp 1111-1122, issn 0269-2813, 12 p.Article